This strategic milestone concludes national reliance on sending plasma abroad for fractionation, anchoring the production of critical plasma-derived therapeutics within domestic borders.
Elevation of quality control standards, bioassays, and biological batch release certification to the tier of regional reference laboratories.
Expansion of the national plasma collection network utilizing fully automated plasmapheresis in compliance with WHO standards.
Mastery of technical formulation for advanced oily emulsion adjuvants to boost vaccine immunological efficacy in the livestock and poultry industries.